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1. Introduction 
Pharmaceutical stability may be defined as the capability of a particular formulation, in a 
specific container/closure system, to remain within its physical, chemical, 
microbiological, therapeutic, and toxicological specifications, during transport, storage 
and use. Chemical degradation may results in a loss of potency or an increase in drugs 
toxicity, so that clinical use of a medicine must be unacceptable if the degradation is 
relatively great. When a drug dosage form is altered (by dissolution, pulverization, or 
addition to other materials) or the environment of the drug is modified by changes in 
storage conditions, the stability of a drug may be affected [1-5]. Although there are 
exceptions, 90% of labeled potency generally is recognized as the minimum acceptable 
potency level (Gennaro, 2000). 
Stability testing forms an important part of the process of drug development; it provides 
evidence on how the quality of drug substance or drug product varies with time under the 
influence of a variety of environmental factors, such as humidity, temperature, and light. 
The stability studies of drugs can be performed at the original product (“real-time” tests or 
long-term tests at specific temperatures and relative humidity representing storage 
conditions experienced in the distribution chain of the climatic zone(s) of the country or 
region of the world concerned; accelerated stability tests; pharmacies storage tests) or at 
remainder doses of these products. The chemical stability is evaluated by testing quantity of 
drug at different time during the storage (Lund, 1994; USP, 2007).  
The aim of the stability studies is to determine the shelf life of the product and its optimum 
storage conditions (Connors et al., 1986; Lund, 1994; The Sixth ICH International Conference 
on Armonization of Technical Requirements for Registration of Pharmaceuticals for Human 
Use [ICH], 2003; The United States Pharmacopeia [USP], 2007; Watson, 2005; Yoshioka, 
2000). 
Therefore, the authors have been developing and validating HPTLC methods with the aim 
of quantification of drugs in dosage forms, suitable for stability and quality control studies, 
as at original products as at its remainder doses. 
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2. Drugs 
Some drugs analyzed by HPTLC developed methods had been Fluphenazine, Haloperidol 
and L-DOPA. 
2.1 Fluphenazine 
Fluphenazine is a phenotiazine antipsychotic agent. The drug is a propylpiperazine 
derivative of phenotiazine (Delgado et al., 1998; Hardman & Limbird, 2006; Mc Evoy, 2006; 
Sweetman, 2003).  
 
 
Fig. 1. Chemical structure of Fluphenazine 
 
 
Fig. 2. Chemical structure of Haloperidol 
Drug therapy with fluphenazine is integral for the management of acute psychotic episodes 
with violent behavior in patients with schizophrenia and generally is required for long-term 
stabilization to improve symptoms between episodes and to minimize the risk of recurrent 
acute episodes (Hardman & Limbird, 2006; Mc Evoy, 2006; Sweetman, 2003). 
Fluphenazine hydrochloride, decanoate, and enantate are all sensitive to light. Therefore, it 
is very important to determine the quantity of fluphenazine in its dosage forms because in 
the presence of light, photolysis occur rapidly, resulting in drug loss and potency reduction 
(Delgado et al., 1998; Hardman & Limbird, 2006; Mc Evoy, 2006; Moffat el al, 2004; 
Sweetman, 2003). 
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2.2 Haloperidol 
Haloperidol, a butyrophenone derivative, is used for the symptomatic management of 
psychotic disorders, in the same way that fluphenazine (Delgado et al., 1998; Hardman & 
Limbird, 2006; Mc Evoy, 2006; Sweetman, 2003). 
When haloperidol injection is used, dose is depending on the severity of the illness, the age 
of the patient and on their response to the pharmacotherapy. Therefore, sometimes the dose 
corresponed only to a portion of the injection. The portion which is not used is stored for the 
next administration or is discarded (Delgado et al., 1998; Hardman & Limbird, 2006; Mc 
Evoy, 2006). The stability of this portion is unknown. 
2.3 L-DOPA 
L-DOPA, the levorotatory isomer of dihydroxyphenylalanine, a natural amino acid, is the 
precursor of the neurotransmitter dopamine.  
 
 
Fig. 3. Chemical structure of L-DOPA 
The actions of L-DOPA are mainly those of dopamine. Unlike dopamine, L-DOPA can 
readily enter the Central Nervous System and is used in the treatment of conditions, such as 
Parkinson´s disease, which are associated with depletion of dopamine in the brain (Delgado 
et al., 1998; Hardman & Limbird, 2006; Mc Evoy, 2006, Sweetman, 2003). L-DOPA is 
considered by many clinicians the drug of choice in the management of idiopathic 
parkinsonian syndrome (Mc Evoy, 2006). 
It is very important to determine the quantity of L-DOPA in its dosage forms, because, in 
the presence of moisture or atmospheric oxygen, it is rapidly oxidized resulting in drug loss 
and potency reduction (Carstensen, 1990; Mc Evoy, 2006; USP, 2007; Sweetman, 2003). 
3. Methods 
Some methods have been reported for the analysis of fluphenazine, haloperidol and L-
DOPA in pharmaceutical preparations or in biological fluids. These methods include: 
spectrophotometry (Blanco et al., 2000; Damiani et al., 2005; Karpinska et al., 2005; 
Madrakian et al., 2004; Madrakian et al., 2006; Marcolino-Junior et al., 2001; Nagaraja et al., 
2001; Nagaralli et al., 2002; Nour El-Dien et al., 2005; Pistonesi et al., 2004; Talebpour et al., 
2005), gas chromatography (Jemal et al., 2005), liquid chromatography (Ali & Aboul-Enein, 
2005; Chaná et al., 2004; Crevoisier et al., 2003; Fernández et al., 2001; Karimi et al., 2006; 
Kircherr & Kühn-Velten, 2006; Lea et al., 1982; Nyholm et al., 2002; Sagar & Smyth, 2000; 
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Saxer et al., 2004; Trabelsi et al., 2002; Wang & Fang, 2006), electrophoresis ( Zhang et al., 
2001) and voltammetry (Maia et al., 2005). Nevertheless, these methods have often suffered 
from diverse disadvantages with regard to cost or selectivity, with complex sample 
preparation procedures, and long analysis time. 
Also, one method by TLC was found for determination of fluphenazine hydrochloride in 
coated tablets, but not in ampoules (Maslanka & Krzek, 2005). Only one paper of stability of 
haloperidol in injections is discussed in literature, but this paper deals whit the stability of 
haloperidol in 5% dextrose injection (Das Gupta & Stewart, 1982).  
3.1 High performance thin layer chromatography (HPTLC) 
High performance of HPTLC is due to it fastness, solvent economy and high throughput of 
samples. Chromatography of samples simultaneously with standards it is another 
advantage, allowing to run up to 60 spots simultaneously (27 samples plus standards by 
each side of the plate). Sensitivity of HPTLC is normally in the range of nanograms in 
absorbance and picograms in fluorescence mode.  
The authors have performed some works using HPTLC for quantitative determination of 
drugs in biological fluids (Mennickent et al., 2003,2007a, 2007b, 2009, 2010a, 2010b) and in 
dosage forms ( de Diego et al., 2007a, 2007b, 2010a, 2010b; Mennickent et al., 2007a, 2007b, 
2007c, 2010), with exact and reliable results. 
The HPTLC methods developed are simples, rapids, with low LOD and LOQ values, with 
very good accuracy and precision, with robustness, and economical. 
3.1.1 Method for fluphenazine injections 
For the quantification of fluphenazine in injections, the method was linear in the range of 
100 ng/band to 500 ng/band (r=0.998).The limit of detection (LOD) and limit of 
quantification (LOQ) were 1.45 ng/band and 4.40 ng/band, respectively. The intra-assay 
and inter-assay precision, expressed as the relative standard deviation (RSD), 
were in the range of 0.73%-1.77% (n=3) and 1.18%-1.86% (n=9), respectively. The recovery of 
fluphenazine hydrochloride was in the range 98.29% and 101.53%, with a RSD not higher 
than 1.87%. The method was selective for fluphenazine hydrochloride from the 
preservatives of the injections (Rf for fluphenazine hydrochloride was 0.33, whereas 
parabens run to the solvent front) (Fig. 4 and Fig. 5). 
Stability-indicating capability of the HPTLC assay was studied by forced decomposition of 5 
mL of a solution of fluphenazine 1 mg/mL, with 10 mL of 0.1 N hydrochloric acid, 10 mL of 
0.1 N sodium hydroxide and 10 mL of 3% H2O2. The mixtures with NaOH and with HCl 
were heated on hot plates at 60ºC for 60 minutes. The mixture with H2O2 was storage at 
room temperature (25ºC) for 60 minutes. Then, each mixture was diluted to 100 ng/uL with 
ethanol and analyzed. 
Also, stability-indicating capability of the assay was proved by conducting forced 
degradation conditions of UV and VIS radiation on fluphenazine standard, as solution of 
100ng/uL. 
One degradation product was found after treatment of fluphenazine with HCl, and two 
degradation products were found after treatment with NaOH. Rf for fluphenazine was 0.30, 
whereas Rf for degradation product with HCl was 0.01, and Rf for degradation products 
with NaOH were 0.03 and 0.23 respectively. None degradation product was found with 
H2O2 (Fig.6).  
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Fig. 4. Selectivity of the method. Study with parabens. Peak observed: fluphenazine. Rf: 
retarding factor. AU: absorbance unit 
 
 
Fig. 5. Picture (video store, CAMAG) of plate at selectivity with parabens. Tracks 1-3 (from 
left to right of the plate) : fluphenazine hydrochloride; tracks 4-6: fluphenazine 
hydrochloride + methylparaben; tracks 7-9: fluphenazine hydrochloride + propylparaben; 
tracks 10-12: fluphenazine hydrochloride + methylparaben + propylparaben. Bands of 
parabens can be observed at the solvent front 
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Fig. 6. Degradation study of fluphenazine with HCl, with NaOH and with H2O2. Tracks 1-3 
(from bottom side to the upper side): fluphenzine; tracks 4-6: fluphenazine + HCl; tracks 7-9: 
fluphenazine + NaOH; track 10-12: fluphenazine + H2O2. Rf peak pluphenazine = 0.30. 
Other peaks at tracks 4-9: degradation products. Rf: retarding factor. AU: absorbance unit 
 
 
Fig. 7. Degradation study of fluphenazine with VIS radiation. Peak 1 (from left to right): 
fluphenazine; peak 2: degradation product. Rf: retarding factor: AU: absorbance unit 
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When the drug was exposed to forced degradation with VIS radiation, another peak 
different to the peak of fluphenazine was found, therefore it could be a degradation product. 
Rf for fluphenazine = 0.30 and Rf for degradation product = 0.56 (Fig. 7). One of the 
products of photolysis mentioned in literature is a sulphoxide (Lund, 1994). 
Values for precision study of the method can be observed at the Table 1.  
 
Relative standard deviation (RSD), % 
Concentration (ng/uL) Intraassay precisionª Intermediate precisionb 
100 1.77 1.86 
300 1.64 1.47 
500 0.73 1.18 
a n= 3; analyzed on the same day (for each concentration) 
b n= 9; analyzed on three different days (for each concentration) 
Table 1. Precision of the HPTLC method for fluphenazine injections 
Values founded for the accuracy of the method are presented at the Table 2. 
 
Added concentration
(ng/uL) 
Found concentration
(ng/uL) a 
Accuracy, % b RSD, % c 
Intraassay (n=9) 
80 79.90 ± 1.31 99.87 1.64 
100 100.45 ± 1.10 100.45 1.10 
120 121.84 ± 2.28 101.53 1.87 
Interassay (n=27) 
80 78.63 ± 1.34 98.29 1.71 
100 99.74 ± 1.65 99.74 1.65 
120 120.90 ± 1.83 100.75 1.52 
a Each value is the mean ± standard deviation. 
b (Founded concentration/ added concentration) x 100. 
c Relative standard deviation (coefficient of variation). 
Table 2. Method accuracy 
3.1.2 Method for haloperidol injections 
For the quantification of haloperidol in injections, the method was linear between 
10ng/band to 100 ng/band (r = 0.999), the method was selective between haloperidol and 
the parabens, the preservatives in haloperidol lactate injection (Rf for haloperidol was 0.70, 
whereas parabens run to the solvent front) (Fig. 8-10). RSD for precision was ≤ 1.92%, and 
accuracy was from 98.59% to 101.90% of recovery. LOD was 0.89 ng/band and LOQ was 
2.71 ng/band. 
Stability-indicating capability of the HPTLC assay was established by forced decomposition 
of 5 mL of a solution of haloperidol lactate 1 mg/mL, with 10 mL of 0.1 N hydrochloric acid 
and 10 mL of 0.1 N sodium hydroxide. The mixture was heated on a hot plate at 60ºC for 60 
minutes, cooled to room temperature, diluted to 100 ng/uL with methanol and analyzed. 
Also, stability-indicating capability of the assay was proved by conducting forced 
degradation conditions of VIS radiation on haloperidol standard. 
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Fig. 8. Peak of haloperidol. Rf: retarding factor: AU: absorbance unit. Solution concentration: 
80 ng/uL 
 
 
Fig. 9. Selectivity of the method. Study with parabens. Tracks 1-3 (from the bottom side to 
the upper side): haloperidol; tracks 4-6: haloperidol + methylparaben; tracks 7-9: haloperidol 
+ propylparaben; tracks 10-12: haloperidol + methylparaben + propylparaben.  Peak 1(from 
left to right): haloperidol; peak 2: solvent front. Rf: retarding factor. AU: absorbance unit 
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Fig. 10. Picture (video store, CAMAG) of plate at selectivity between haloperidol and 
parabens. Tracks 1-3: haloperidol; tracks 4-6: haloperidol + methylparaben; tracks 7-9: 
haloperidol + propylparaben; tracks 10-12: haloperidol + methylparaben + propylparaben. 
Bands of parabens can be observed at the solvent front 
After treatment of haloperidol lactate with acid none degradation product was found. 
However, after treatment with basic, one minor peak was found, which probably correspond 
to a degradation product, with a resolution of 2.4 between haloperidol and another peak 
(Fig. 11) 
 
 
Fig. 11. Selectivity of the method. Study at forced degradation of haloperidol with 0.1 N HCl 
and 0.1 N NaOH. Tracks 1,2,7,8 (from the bottom side to the upper side): haloperidol; tracks: 
3-4: haloperidol + HCl; tracks 5-6: haloperidol + NaOH.  Peak 1 (from left to right): 
haloperidol; peak 2: solvent front. Minor peak at tracks 5-6: degradation products. Rf: 
retarding factor: AU: absorbance unit 
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When the drug was exposed to forced degradation with VIS radiation, no degradation 
product was found.  
The degradation products for haloperidol mentioned in literature are acrolein, chlorobenzene, 
p-fluorobenzaldehyde, p-fluoroacetophenone, p-fluorophenyl propenyl ketone, when 
haloperidol was irradiated with a sterilising dose of gamma radiation (Lund et al., 1994). 
Another studies found 4-(4-chlorophenyl)-4-hidroxypiperydine and 4-fluorobenzoic acid, 
presumed to be hydrolytic products of haloperidol (Jemal et al., 2005; Karipnska et al., 2005) 
and 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone N-oxide; 
and 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-hydroxyphenyl)-1-butanone;  
4-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-piperidinyl]-1-(4-fluorophenyl)-1-butanone (Lund 
et al., 1994). 
Values for the precision study are shown at the Table 3. 
 
Relative standard deviation (RSD), % 
Concentration 
(ng/uL) 
Instrumental 
precisiona 
Intraassay 
precisionb 
Intermediate 
precisionc 
10 0.81 1.31 1.92 
50 0.37 1.74 1.53 
100 0.51 0.38 1.11 
a n= 10; analyzed on the same day 
b n= 5; analyzed on the same day (for each concentration) 
c n= 9; analyzed on three different days (for each concentration) 
Table 3. Precision of the method 
Values for the accuracy of the method can be observed at the Table 4. 
 
Added concentration 
(ng/uL) 
Found concentration
(ng/uL) a 
Accuracy, % b  
Intraassay (n=9) 
80 78.87 ± 2.98 98.59 3.78 
100 101.21 ± 3.78 101.21 3.74 
120 119.05 ± 1.75 99.21 1.47 
Interassay (n=27) 
80 81.52 ± 3.59 101.90 4.40 
100 99.74 ± 4.41 99.74 4.42 
120 119.35 ± 5.37 99.46 4.50 
a Each value is the mean ± standard deviation.;  
b (Founded concentration/ added concentration) x 100; 
c Relative standard deviation (coefficient of variation). 
Table 4. Method accuracy 
Stability study of haloperidol lactate injection 5mg /mL was realized at the following 
conditions: 25 ± 2 ºC, because it is the more common temperature founded at hospitals in Chile 
and is the temperature mentioned by ICH guidelines for stability studies at dosage forms; and 
refrigeration temperature (8 ± 1 ºC) in its original glass ampoules after it was opened, removed 
a portion of drug, and sealed with Teflon. The samples at room temperature were stored 
under light exposure and light protection. The study was performed over 15 days. 
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Samples were taken at appropriate time intervals (0, 3, 5, 7, 10 and 15 days), and analyzed in 
duplicate by HPTLC to determine haloperidol concentration. For stability study, 100 uL of 
the haloperidol lactate injection 5 mg/mL was transferred to a 10 mL volumetric flask and 
diluted with methanol to volume (final concentration of 50 ng/uL). 
The percentage of haloperidol remaining after each interval was determined by comparing 
the concentration at that time with the initial haloperidol concentration, measured before 
storage (t = 0) at the different conditions. Haloperidol lactate injections, when stored at 25 ± 
2 ºC under light exposure and light protection, and when stored at refrigeration temperature 
(8 ± 1 ºC) in original glass ampoules opened and after closed with Teflon retained at least 
90% of the initial concentration over 15 days (Table 5). 
 
Storage time 
(days) 
Initial concentration remaining (%) (Mean ± SD) 
 23 ± 2 ºC 8 ± 1 ºC 
 Exposed to light Protected from light 
0 100 .00 100.00 100.00 
3 94.77 ± 0.6 96.20 ± 2.1 98.99 ± 0.3 
5 93.64 ± 1.4 94.79 ± 0.8 98.75 ± 1.2 
7 93.26 ± 2.1 93.20 ± 1.8 96.99 ± 1.4 
10 91.87 ± 0.3 92.88 ± 2.0 94.75 ± 2.1 
15 90.69 ± 1.7 91.71 ± 0.5 92.53 ± 0.8 
Table 5. Stability of injectable haloperidol 
3.1.3 Method for L-DOPA tablets 
For the quantification of L-DOPA in tablets, the method was linear between 100 ng/band to 
500 ng/ band (r = 0.999). The intra-assay variation was between 0.26% and 0.65% and the 
inter-assay was between 0.52% and 2.04%. LOD was 1.12 ng, and LOQ was 3.29 ng. The 
accuracy ranged from 100.40 % to101.09%, with a coefficient of variation not higher than 
1.40%. The method was selective for L-DOPA (Rf = 0.37) and carbidope (Rf = 0.79) (Fig. 12). 
Table 6 shown the values for the precision study of the method. 
The values found for the accuracy of the method can be observed at Table 7. 
At Table 8 can be observed the values found for the determination of L-DOPA in tablets by 
the proposed HPTLC method and by the USP HPLC method. 
Accelerated stability study was performed on commercial tablets of L-DOPA. The 
temperature used was 40±2ºC and the relative humidity was 75±5 (Zone II, OMS). The study 
was carried out by three months, taking samples to t=0 and one time each month. 
 
Relative standard deviation (RSD), % 
Concentration 
(ng/μL) 
Instrumental 
precisiona 
Intraassay 
precisionb 
Intermediate 
precisionc 
100 0.45 0.48 2.04 
300 0.68 0.65 0.77 
500 0.23 0.26 0.52 
a n= 10; analyzed on the same day; b n= 5; analyzed on the same day (for each concentration) 
c n= 9; analyzed on three different days (for each concentration) 
 
Table 6. Precision of the method 
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Fig. 12. Selectivity of the method. Peak 1 (from left to right): L-DOPA; peak 2: Carbidope 
(dopa-decarboxilase inhibitor) 
 
Added concentration (ng/μL) Found concentration (ng/μL) a Accuracy, % b RSD, % 
Intraassay (n=9) 
320 322.10 ± 4.20 100.66 1.30 
400 404.22 ± 3.70 101.06 0.92 
480 485.25 ± 1.20 101.09 0.25 
Interassay (n=27) 
320 321.27 ± 4.50 100.40 1.40 
400 402.30 ± 3.80 100.58 0.94 
480 482.83 ± 2.35 100.60 0.49 
a Each value is the mean ± standard deviation; b (Found concentration/ added concentration) x 100. 
Table 7. Method accuracy 
 
Parameter HPTLC HPLC 
Labelled claim (mg per tablet) 100.00 100.00 
Amount founda (mg per tablet) 90.99 90.00 
RSD (%) 2.40 1.53 
F calc.: 11.86; F theoreticalb: 13.61   
a Each result is the mean of nine experiments (three solutions, three determinations of each of them). 
b α = 0.05 
Table 8. Comparison for determination of L-DOPA in tablets by the proposed method and 
by HPLC 
Tablets were processed as follow (USP, 2007): 20 tablets were weighed and ground into fine 
powder and an accurately weighed portion equivalent to 30 mg of L-DOPA was diluted to 
100 mL with water: methanol (7:3, v/v) . The solution was centrifuged and then, 1 mL of the 
supernatant was diluted to a 10 mL with the mixture solvent.  
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Results of the accelerated stability study can be observed at Table 9. 
 
t(months) Percentage L-DOPA per tablet Quantity L-DOPA per tablet (mg) 
0 100.00 90.99 
1 96.65 87.94 
2 87.21 79.35 
3 85.60 77.89 
Table 9. Results for the accelerated stability study of L-DOPA tablets 
Therefore, at the second month of accelerated stability study, L-DOPA tablets don’t have a 
change significant at the percentage of active principle per tablet, but at the third month of 
the study, the change at the percentage is more than a 5% (ICH, 2003). 
4. Conclusion 
The proposed HPTLC methods are a new analytical alternative for quantification of the 
mentioned drugs in these dosage forms. None HPTLC method for quantitative analysis of 
fluphenazine hydrochloride in injections, haloperidol in injections and L-DOPA in tablets 
were found in literature before our methods. 
These methods are simple, fast, precise, sensitive (low LOD and LOQ values), accurate and 
specifics for the quantification of these drugs in the dosage forms studied. Moreover, 
HPTLC allows for a large number of samples to be measured simultaneously, very 
important, especially in quality control.  
The procedure works without separation steps, only centrifugation, because the excipients 
are not dissolved by the working solvents. 
Therefore, the proposed HPTLC methods are very good methods for quantitative analysis of 
fluphenazine hydrochloride in injection, haloperidol lactate in injections, and L-DOPA in 
tablets, being appropriates to stability studies. 
By the other side, the results indicate that haloperidol lactate injection (glass ampoules) 
could be stored for at least 15 days and use when needed, reducing wastage and 
unnecessary expenses. This could result in substantial money savings for some institutions. 
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